ERAS 2021: CHF Solutions to Host On-Demand Presentation on Management of Fluid Overload in Cardiac Surgery Patients
March 04 2021 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, will
participate in the first ERAS Cardiac Society Virtual Conference,
broadcasting Live from Methodist Hospital DeBakey Center in
Houston, Texas on March 5-6, 2021.
Daniel Beckles, MD, PhD, FACS, Surgical Director Heart of
Transplantation and MCS at Baylor Scott & White Health Central
Texas, will present an on-demand lecture on the management of fluid
overload with Aquadex™ ultrafiltration therapy. He will discuss the
morbidity and mortality issues surrounding fluid overload in
patients undergoing cardiac surgery, the cardio-renal connection,
and how to best manage these patients. Dr. Beckles will share best
practices and real-world experience on improving patient
outcomes.
CHF Solutions will also have a virtual booth with live chat
features to connect attendees directly to company representatives
who can answer questions about the use of Aquadex SmartFlow® in
cardiac surgery and critical care applications.
“Fluid overload is extremely common after cardiac procedures and
can lead to ongoing cardio-renal complications. There’s work to be
done in educating providers on best practices for effectively
maintaining hemodynamic stability to prevent adverse outcomes,”
said Nestor Jaramillo, Jr., President and CEO of CHF Solutions.
“ERAS brings together some of the smartest and brightest experts
from around the globe to incite collaboration to optimize outcomes,
and we’re honored Daniel Beckles, MD, PhD, FACS is able to share
his experience using Aquadex to improve how fluid overloaded
patients are treated.”
Register to attend the 2021 ERAS Cardiac Society Virtual
Conference by following this link.
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to changing the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the
company’s activities around the ERAS Cardiac Society Virtual
Conference. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024